Log in
NASDAQ:CDLX

Cardlytics Stock Forecast, Price & News

$68.74
+3.10 (+4.72 %)
(As of 09/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$64.63
Now: $68.74
$69.58
50-Day Range
$64.26
MA: $73.39
$85.72
52-Week Range
$27.33
Now: $68.74
$107.50
Volume759,292 shs
Average Volume764,782 shs
Market Capitalization$1.88 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.32
Cardlytics, Inc. operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. It also provides solutions that enable marketers and marketing service providers to leverage the power of purchase intelligence outside the banking channel. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Read More
Cardlytics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars


Industry, Sector and Symbol

Industry Computer programming, data processing, & other computer related
Sub-IndustryN/A
Current SymbolNASDAQ:CDLX
CUSIPN/A
Phone888-798-5802

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$210.43 million
Book Value$6.28 per share

Profitability

Net Income$-17,140,000.00

Miscellaneous

EmployeesN/A
Market Cap$1.88 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$68.74
+3.10 (+4.72 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CDLX News and Ratings via Email

Sign-up to receive the latest news and ratings for CDLX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cardlytics (NASDAQ:CDLX) Frequently Asked Questions

How has Cardlytics' stock been impacted by Coronavirus (COVID-19)?

Cardlytics' stock was trading at $45.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CDLX stock has increased by 50.0% and is now trading at $68.74.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Cardlytics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Cardlytics
.

When is Cardlytics' next earnings date?

Cardlytics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Cardlytics
.

How were Cardlytics' earnings last quarter?

Cardlytics Inc (NASDAQ:CDLX) announced its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.38) EPS for the quarter, beating the Zacks' consensus estimate of ($0.74) by $0.36. The company had revenue of $28.22 million for the quarter, compared to the consensus estimate of $30.84 million. Cardlytics had a negative net margin of 18.86% and a negative return on equity of 26.42%. The company's revenue for the quarter was down 42.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.12) earnings per share.
View Cardlytics' earnings history
.

What price target have analysts set for CDLX?

6 brokerages have issued twelve-month price targets for Cardlytics' stock. Their forecasts range from $26.00 to $80.00. On average, they expect Cardlytics' share price to reach $59.33 in the next year. This suggests that the stock has a possible downside of 13.7%.
View analysts' price targets for Cardlytics
.

Who are some of Cardlytics' key competitors?

What other stocks do shareholders of Cardlytics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include NVIDIA (NVDA), Square (SQ), Docusign (DOCU), Advanced Micro Devices (AMD), Caterpillar (CAT), Trade Desk (TTD), Walt Disney (DIS), Alibaba Group (BABA), QUALCOMM (QCOM) and Roku (ROKU).

Who are Cardlytics' key executives?

Cardlytics' management team includes the following people:
  • Mr. Scott D. Grimes, Co-Founder, CEO & Director (Age 56)
  • Ms. Lynne Marie Laube, Co-Founder, COO & Director (Age 49)
  • Mr. David Evans, CFO & Head of Corp. Devel.
  • Mr. Sathish Gaddipati, Chief Technology Officer (Age 52)
  • Mr. Kirk L. Somers, Chief Legal & People Officer (Age 54)

When did Cardlytics IPO?

(CDLX) raised $76 million in an initial public offering (IPO) on Friday, February 9th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan served as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

What is Cardlytics' stock symbol?

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Who are Cardlytics' major shareholders?

Cardlytics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.70%), Bank of New York Mellon Corp (1.76%), Frontier Capital Management Co. LLC (1.67%), Jennison Associates LLC (1.63%), Grantham Mayo Van Otterloo & Co. LLC (1.51%) and Victory Capital Management Inc. (1.16%). Company insiders that own Cardlytics stock include Aimia Inc, Andrew Christiansen, Bryce Youngren, Clifford Sosin, David Leslie Adams, David Thomas Evans, John L Jr Klinck, John V Balen, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Polaris Venture Management Co, Scott D Grimes and Tony Weisman.
View institutional ownership trends for Cardlytics
.

Which institutional investors are selling Cardlytics stock?

CDLX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Grantham Mayo Van Otterloo & Co. LLC, Pier Capital LLC, RMB Capital Management LLC, Great West Life Assurance Co. Can, Two Sigma Advisers LP, Crosslink Capital Inc., and Teton Advisors Inc.. Company insiders that have sold Cardlytics company stock in the last year include Andrew Christiansen, Bryce Youngren, David Leslie Adams, David Thomas Evans, John L Jr Klinck, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Scott D Grimes, and Tony Weisman.
View insider buying and selling activity for Cardlytics
.

Which institutional investors are buying Cardlytics stock?

CDLX stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Great Lakes Advisors LLC, Nordea Investment Management AB, Clearfield Capital Management LP, Driehaus Capital Management LLC, Nuveen Asset Management LLC, First Trust Advisors LP, and Serengeti Asset Management LP. Company insiders that have bought Cardlytics stock in the last two years include Clifford Sosin, and John V Balen.
View insider buying and selling activity for Cardlytics
.

How do I buy shares of Cardlytics?

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cardlytics' stock price today?

One share of CDLX stock can currently be purchased for approximately $68.74.

How big of a company is Cardlytics?

Cardlytics has a market capitalization of $1.88 billion and generates $210.43 million in revenue each year. The company earns $-17,140,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

What is Cardlytics' official website?

The official website for Cardlytics is www.cardlytics.com.

How can I contact Cardlytics?

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at 888-798-5802 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.